Sirt5 Antibody

What is SIRT5 and why is it important in scientific research?

SIRT5 is a member of the sirtuin family of proteins, which are homologs to the yeast Sir2 protein. It is the only human class III sirtuin and serves as the closest homolog to bacterial (e.g., E. coli CobB) and archaeal sirtuins . SIRT5 functions as a mitochondrial matrix NAD(+)-dependent deacetylase and mono-ADP-ribosyltransferase that plays critical roles in various cellular processes .

What distinguishes SIRT5 from other sirtuins is its efficient protein lysine desuccinylase and demalonylase activity. During prolonged fasting, it can activate CPS1, a key enzyme in the urea cycle . Recent research has identified SIRT5 as a potential therapeutic target in certain cancers, particularly Acute Myeloid Leukemia (AML), where many primary samples and cell lines are dependent on SIRT5 for survival and growth .

SIRT5 exists as a ~34 kDa precursor protein that is processed to a predominant ~29-33 kDa form after mitochondrial import and processing .

What applications are SIRT5 antibodies suitable for?

SIRT5 antibodies have been validated for multiple experimental applications with specific recommended dilutions:

SIRT5 antibodies have been successfully tested in various cell lines including HeLa, HEK-293, L02, LNCaP, and K-562 cells . For IHC applications, positive detection has been reported in human liver cancer tissue and human heart tissue .

How should SIRT5 antibodies be stored and handled for optimal performance?

Proper storage and handling of SIRT5 antibodies are essential for maintaining their performance:

Some manufacturers note that specific formulations (e.g., 20μl sizes) may contain 0.1% BSA . For lyophilized antibodies, reconstitution typically involves adding a specified volume (e.g., 50 μL) of distilled water to achieve a final concentration of 1 mg/mL .

What are the critical parameters for optimizing SIRT5 antibody performance in Western blot applications?

Optimizing Western blot protocols for SIRT5 detection requires attention to several key parameters:

• Expected Molecular Weight: The calculated molecular weight of SIRT5 is 34 kDa, but the observed molecular weight is typically around 33 kDa for the full-length protein and ~29 kDa for the processed mitochondrial form .

• Dilution Optimization: Start with the manufacturer's recommended range (1:2000-1:10000 for monoclonal antibodies or 1:2500-1:3000 for polyclonal antibodies ), then adjust based on signal intensity.

• Detection Systems: Both colorimetric (using secondary antibody coupled to alkaline phosphatase and BCIP/NBT as substrate) and ECL (using secondary antibody coupled to HRP) methods have been validated .

• Positive Controls: Include validated cell lines such as HeLa, HEK-293, L02, LNCaP, or K-562 cells as positive controls .

• Sample Preparation: Given SIRT5's mitochondrial localization, ensure proper lysis conditions to extract mitochondrial proteins effectively.

Optimization should be performed systematically, changing one parameter at a time and documenting results to identify optimal conditions for your specific experimental system.

What methodological approaches should be used for validating SIRT5 antibody specificity?

Validating antibody specificity is critical for ensuring reliable research outcomes. For SIRT5 antibodies, implement the following methodological approach:

• Genetic Controls: Utilize SIRT5 knockout or knockdown models as negative controls. Studies with SIRT5-deficient models can serve as references for expected results .

• Recombinant Protein Controls: Run purified recombinant SIRT5 alongside your samples in Western blots to confirm correct molecular weight detection.

• Cross-reactivity Assessment: Test for potential cross-reactivity with other sirtuin family members. Some SIRT5 antibodies have been verified to show no cross-reactivity with SIRT1, SIRT2, or SIRT3 .

• Peptide Competition Assay: Pre-incubate the antibody with the immunizing peptide prior to application. Signal reduction confirms specific binding.

• Multi-antibody Validation: Compare results using antibodies from different sources or those recognizing different epitopes of SIRT5.

For cellular localization studies, it's important to note that SIRT5 is primarily mitochondrial, so proper mitochondrial markers should be used as co-localization controls in immunofluorescence experiments.

How should researchers optimize immunohistochemistry protocols for SIRT5 detection in tissue samples?

For successful IHC detection of SIRT5 in tissue samples, consider the following methodological guidelines:

• Antigen Retrieval: For optimal results, use TE buffer at pH 9.0. Alternatively, citrate buffer at pH 6.0 may also be effective .

• Antibody Dilution: Start with a dilution range of 1:250-1:1000 for monoclonal antibodies, then optimize based on signal-to-noise ratio .

• Tissue Selection: Human liver cancer tissue and human heart tissue have been validated for positive SIRT5 detection .

• Controls: Include both positive controls (known SIRT5-expressing tissues) and negative controls (primary antibody omission or isotype controls).

• Signal Development: Optimize incubation times for primary and secondary antibodies, as well as for chromogenic development to achieve optimal signal intensity while minimizing background.

• Counterstaining: Adjust counterstaining protocols to ensure visibility of SIRT5 staining pattern without obscuring specific signals.

Remember that optimal conditions may vary between different tissue types and fixation methods, necessitating systematic optimization for each specific application.

How can SIRT5 antibodies be utilized to investigate its role in cellular metabolism?

SIRT5's crucial role in metabolic regulation requires specific experimental approaches:

• Metabolic State Control: Since SIRT5 activates CPS1 during prolonged fasting, compare fed vs. fasted conditions or glucose-deprived vs. normal culture conditions .

• Subcellular Fractionation: As SIRT5 is primarily mitochondrial, conduct proper subcellular fractionation to accurately assess its localization and function using antibody detection in each fraction.

• Post-translational Modification Analysis: Use SIRT5 antibodies in combination with specific PTM detection methods to study its desuccinylase and demalonylase activities on target proteins.

• Co-immunoprecipitation Studies: Employ SIRT5 antibodies for co-IP experiments to identify metabolic interaction partners, followed by mass spectrometry analysis.

• Integrated Experimental Design: Correlate SIRT5 expression/localization (detected by antibodies) with functional metabolic parameters:

  • Oxidative phosphorylation measurements

  • Glutamine utilization assays

  • Mitochondrial superoxide levels

  • CPS1 activity in the urea cycle

Research has shown that SIRT5 disruption leads to reductions in oxidative phosphorylation and glutamine utilization, with increased mitochondrial superoxide . These parameters should be monitored alongside antibody-based detection methods.

What are the methodological approaches for using SIRT5 antibodies in cancer research, particularly AML studies?

SIRT5 has been identified as a druggable metabolic vulnerability in AML, making it an important target for cancer research . Methodological approaches include:

• Comparative Expression Analysis: Use SIRT5 antibodies (WB dilution 1:2000-1:10000) to compare protein levels between cancer cells and normal counterparts, such as AML cells versus normal CD34+ cells .

• Genotype-Phenotype Correlation: Analyze SIRT5 expression across different genetic backgrounds in AML, as dependence on SIRT5 appears to be genotype-agnostic, extending to RAS- and p53-mutated AML .

• Therapeutic Response Monitoring: Use SIRT5 antibodies to monitor protein levels during treatment with inhibitors like NRD167, correlating expression with cellular responses .

• Mechanism Investigation: Combine SIRT5 antibody detection with functional assays that assess:

  • Apoptosis induction following SIRT5 disruption

  • Changes in oxidative phosphorylation

  • Alterations in glutamine utilization

  • Increases in mitochondrial superoxide

• In vivo Studies: Utilize SIRT5 antibodies for IHC analysis of mouse model tissues to correlate protein expression with disease progression following SIRT5 inhibition .

A methodological approach demonstrated in research involves parallel analysis of SIRT5 inhibition (pharmacological) and knockdown (genetic) to distinguish between protein-dependent and activity-dependent effects in cancer cells .

How do you resolve discrepancies in results obtained with different SIRT5 antibodies?

When facing inconsistent results with different SIRT5 antibodies, implement the following systematic troubleshooting approach:

• Antibody Characterization Analysis:

  • Compare epitope recognition regions between antibodies

  • Determine whether antibodies recognize different SIRT5 isoforms or processed forms

  • Assess specificity using recombinant protein and knockout controls

• Technical Validation:

  • Test antibodies side-by-side under identical conditions

  • Perform titration curves for each antibody to ensure optimal detection

  • Evaluate performance across multiple applications (WB, IHC, IF)

• Sample-specific Optimization:

  • Consider tissue/cell-specific processing of SIRT5 (34 kDa precursor vs. 29 kDa processed form)

  • Assess potential post-translational modifications that might affect epitope recognition

  • Evaluate subcellular distribution in different sample types

• Methodological Reconciliation:

  • For critical findings, confirm results with at least two different antibodies

  • Supplement antibody-based detection with functional assays

  • Consider orthogonal approaches such as mRNA expression analysis or genetic manipulation

This systematic approach allows researchers to determine whether discrepancies reflect technical issues or biologically relevant phenomena, such as differential processing or modification of SIRT5 across experimental systems.

How can SIRT5 antibodies be used to investigate its role in immune cell function?

Recent research has examined SIRT5's role in immune cells, particularly CD8+ T cells . Methodological approaches include:

• Comparative Analysis in Different Immune Cell Populations:

  • Use SIRT5 antibodies for WB analysis to compare expression levels across immune cell subsets

  • Correlate expression with functional parameters such as cytokine production and effector function

• Activation-dependent Changes:

  • Monitor SIRT5 expression before and after immune cell activation

  • Use flow cytometry with intracellular staining to assess single-cell SIRT5 expression

• Mitochondrial Function Correlation:

  • Combine SIRT5 detection with mitochondrial membrane potential measurement (e.g., TMRE staining)

  • Research has shown that SIRT5 deficiency decreased TMRE MFI in CD8+ T cells, suggesting altered mitochondrial function

• Differentiation Analysis:

  • Use SIRT5 antibodies to track expression during memory T cell formation

  • Correlate with transcription factors such as Tcf1 and T-bet that regulate T cell differentiation

• In vivo Functional Studies:

  • Use adoptive transfer models with SIRT5-deficient immune cells

  • Correlate SIRT5 expression with recall response capability and cytokine production

Current research suggests that SIRT5 deficiency does not significantly affect CD8+ T cell effector function or memory formation, despite observed changes in mitochondrial membrane potential .

What are the key considerations when choosing between monoclonal and polyclonal SIRT5 antibodies?

Selection between monoclonal and polyclonal SIRT5 antibodies should be based on experimental requirements:

Methodological Decision Framework:

• For Quantitative Applications: Choose monoclonal antibodies for their consistent epitope recognition and lot-to-lot reproducibility.

• For Multi-species Studies: Select polyclonal antibodies with validated cross-reactivity across species of interest .

• For Novel Systems: Polyclonal antibodies may offer advantages due to recognition of multiple epitopes, increasing detection probability.

• For Conformational Studies: Consider epitope location and accessibility, especially for applications involving fixed or partially denatured proteins.

• For Detecting Specific Post-translational Modifications: Use antibodies specifically validated for the modification of interest.

Always validate antibody performance in your specific experimental system regardless of type, and for critical experiments, confirm findings using both antibody types if possible.

How should researchers troubleshoot weak or absent SIRT5 signals in Western blot applications?

When encountering weak or absent SIRT5 signals in Western blot, implement this systematic troubleshooting approach:

• Sample Preparation Optimization:

  • Ensure efficient lysis of mitochondria using appropriate buffers

  • Consider subcellular fractionation to enrich for mitochondrial proteins

  • Add protease inhibitors to prevent degradation during processing

  • Optimize protein loading (start with 20-50 μg total protein)

• Transfer Efficiency Verification:

  • Use reversible staining of membranes post-transfer to confirm successful protein transfer

  • Adjust transfer conditions for mitochondrial proteins (time, voltage, buffer composition)

• Antibody Optimization:

  • Test concentration gradients (from 1:1000 to 1:10000 for monoclonal antibodies )

  • Extend primary antibody incubation time (overnight at 4°C)

  • Try different blocking agents (BSA vs. milk)

  • Ensure antibody storage conditions match manufacturer recommendations (-20°C, avoid freeze/thaw )

• Detection System Enhancement:

  • Switch between detection methods (ECL vs. colorimetric)

  • Use higher sensitivity ECL substrates for weak signals

  • Extend exposure times systematically

  • Consider signal amplification systems for very low abundance

• Positive Control Implementation:

  • Include validated positive controls (HeLa, HEK-293, L02, LNCaP, or K-562 cells)

  • Consider running recombinant SIRT5 protein as a standard

This methodical approach allows identification of the specific issue limiting SIRT5 detection, enabling targeted improvements to experimental protocols.

What experimental designs are most effective for studying SIRT5 post-translational modifications using antibodies?

Studying SIRT5's post-translational modifications requires specialized experimental approaches:

• PTM-specific Antibody Selection:

  • Use antibodies specifically raised against modified SIRT5 (phosphorylated, acetylated, etc.)

  • Validate specificity using recombinant proteins with and without modifications

• Enrichment Strategies:

  • Implement phospho-enrichment techniques (e.g., TiO2 chromatography) before antibody detection

  • Use specific PTM purification kits to enrich modified proteins prior to Western blot

• Two-dimensional Analysis:

  • Combine immunoprecipitation with SIRT5 antibodies followed by detection with PTM-specific antibodies

  • Alternatively, perform IP with PTM antibodies followed by SIRT5 detection

• Stimulation-response Experiments:

  • Design experiments comparing basal vs. stimulated conditions known to induce specific PTMs

  • Include appropriate time courses to capture transient modifications

• Inhibitor Studies:

  • Use specific inhibitors of modifying enzymes (kinases, acetyltransferases) to confirm PTM identity

  • Compare SIRT5 function with and without PTMs to establish functional significance

• Mass Spectrometry Verification:

  • Complement antibody-based approaches with mass spectrometry analysis of immunoprecipitated SIRT5

  • Map specific modification sites to correlate with antibody recognition regions

This integrated approach provides robust identification and functional characterization of SIRT5 post-translational modifications, which may regulate its enzymatic activity, localization, or protein interactions.

How can SIRT5 antibodies be utilized in studies exploring its potential as a therapeutic target?

Given SIRT5's emergence as a potential therapeutic target, particularly in AML , antibody-based approaches can be instrumental in drug development efforts:

• Target Validation Studies:

  • Use SIRT5 antibodies to correlate protein expression with sensitivity to SIRT5 inhibitors across cell lines and patient samples

  • Perform IHC analysis of tissues to identify high-expressing populations that might benefit from SIRT5-targeted therapies

• Pharmacodynamic Marker Development:

  • Develop protocols using SIRT5 antibodies to monitor target engagement in response to inhibitor treatment

  • Establish correlations between SIRT5 levels/activity and downstream metabolic effects

• Resistance Mechanism Investigation:

  • Apply SIRT5 antibodies to study expression changes in cells developing resistance to SIRT5 inhibitors

  • Identify compensatory pathways activated upon SIRT5 inhibition

• Combination Therapy Rationale:

  • Use antibody-based detection to study SIRT5 expression changes in response to other therapies

  • Identify synergistic combinations based on mechanistic interactions

• Biomarker Development:

  • Establish standardized IHC protocols (1:250-1:1000 dilution ) for potential diagnostic or prognostic applications

  • Correlate SIRT5 expression with clinical outcomes to identify patient populations most likely to benefit from SIRT5-targeted therapies

Research has shown that survival and growth of many primary AML samples and cell lines, but not normal CD34+ cells, are dependent on SIRT5 , highlighting its potential as a selective therapeutic target.

What are the methodological considerations for using SIRT5 antibodies in multi-omics experimental designs?

Integrating SIRT5 antibody-based detection into multi-omics experimental workflows requires careful planning:

• Sample Preparation Compatibility:

  • Design lysate preparation protocols that allow aliquoting for antibody-based detection and other omics approaches

  • Use non-denaturing conditions when possible to preserve protein complexes for interactome studies

• Parallel Processing Design:

  • Process matched samples for antibody-based SIRT5 detection alongside:

    • Proteomics (changes in global protein expression)

    • Metabolomics (alterations in metabolic pathways)

    • Transcriptomics (compensatory gene expression changes)

• Temporal Coordination:

  • Design time-course experiments that capture both rapid post-translational events (detectable by antibodies) and slower transcriptional responses

• Statistical Analysis Framework:

  • Develop analysis pipelines that integrate quantitative antibody-based data with other omics datasets

  • Use correlation analyses to link SIRT5 levels with specific metabolic or proteomic signatures

• Validation Strategy:

  • Plan orthogonal validation experiments using antibody-based techniques (WB, IHC, IF) to confirm key findings from omics datasets

  • Use genetic manipulation (knockdown/overexpression) to establish causality for correlations identified in multi-omics data

This integrated approach allows researchers to place SIRT5 within broader cellular networks and identify previously unrecognized functions or regulatory mechanisms.